Transmucosal Drug Delivery Systems Market

The transmucosal drug delivery systems market is projected to increase from US$ 82.02 billion in 2024 to US$ 129.46 billion by 2031, with an estimated CAGR of 6.2% during the period from 2025 to 2031.

Analyst Perspective

Transmucosal drug delivery utilizes mucosal membranes, including oral, nasal, rectal, vaginal, ocular, and pulmonary mucosa, for administering drugs. This method offers significant advantages over traditional drug delivery routes, such as enhanced bioavailability, quick onset of action, avoidance of first-pass metabolism, and ease of administration. The report highlights growth opportunities based on current trends in the transmucosal drug delivery systems market and their anticipated effects throughout the forecast period.

Factors Propelling Growth in Transmucosal Drug Delivery Systems

Transmucosal drug delivery is favored for its sustained effectiveness. Noninvasive methods like intranasal, buccal, sublingual, and rectal routes allow for systemic drug delivery without the need for specialized personnel, making them particularly beneficial for caregivers and patients. Additionally, the rapid onset of action and reduced first-pass metabolism make these methods ideal for palliative and end-of-life care, providing quick symptom relief. Consequently, transmucosal delivery systems are increasingly utilized in managing chronic conditions such as cardiovascular diseases, diabetes, and chronic respiratory diseases. A study published by PubMed Central in January 2020 examined the safety and pharmacokinetics of dihydroergotamine (DHE) administered as intranasal DHE powder (STS101), intranasal DHE spray (Migranal), and intramuscular (IM) DHE injection in healthy subjects. The findings indicated that STS101 is a user-friendly, non-injected acute treatment for migraines with a favorable tolerability profile, expected to provide rapid and consistent pain relief while suppressing migraine symptoms without recurrence.

Many pharmacological agents are available in oral transmucosal forms, including cardiovascular drugs, sedatives, and analgesics. Biodegradable oral films facilitate drug delivery into systemic circulation, which is particularly advantageous for patients with dysphagia, frequent vomiting, hypertension, heart attacks, asthma, nausea, paralysis, and mental health disorders. These fast-dissolving oral films are thin adhesive strips placed on the tongue or other oral mucosal tissues.

Thus, the benefits of easy administration, high bioavailability, systemic drug availability, and rapid action are driving the growth of the transmucosal drug delivery systems market.

Strategic Insights

Report Segmentation and Scope

The Global Transmucosal Drug Delivery Systems Market Analysis to 2031 is a comprehensive study of the pharmaceutical sector, focusing on global market trend analysis. The report aims to provide an overview of the market with detailed segmentation based on systems, end users, and geography. It includes key statistics on leading market players and highlights significant trends and opportunities in the market. The scope of the global transmucosal drug delivery systems market report covers North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Insights Based on Systems

The market is categorized into nasopulmonary, buccal & sublingual, vaginal, and other systems. The nasopulmonary segment accounted for the largest share of the transmucosal drug delivery systems market in 2023 and is expected to exhibit the highest CAGR from 2023 to 2031.

Insights Based on End Users

The market is divided into healthcare facilities, homecare settings, and others based on end users. The healthcare facilities segment held the largest market share in 2023, attributed to the availability of superior facilities and skilled healthcare professionals in hospitals. Furthermore, the homecare settings segment is projected to experience the highest CAGR from 2023 to 2031.

Regional Analysis

Geographically, the market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. North America held the largest share of the transmucosal drug delivery systems market in 2023, with the US leading this region. This dominance is due to the rising prevalence of chronic diseases such as diabetes, asthma, and cardiovascular conditions, along with an increasing number of product launches by key industry players.

Scope of the Transmucosal Drug Delivery Systems Market Report

Industry Developments and Future Opportunities:

The forecast for the transmucosal drug delivery systems market can assist stakeholders in planning their growth strategies. According to company press releases, several strategic developments by leading players in the global market are outlined below:

1. In February 2024, Aquestive Therapeutics, Inc. showcased a poster at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting in Washington, DC, presenting positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies on sublingual Anaphylm (epinephrine) film.
2. In August 2022, iX Biopharma Ltd launched IXB-322, a new initiative to expand its pipeline, focusing on developing a sublingual dexmedetomidine wafer for treating agitation in dementia and other conditions. This effort is part of iX Biopharma's strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform technology.
3. In May 2021, Tillotts Pharma AG, part of the Japanese Zeria Group, introduced a new medication to its gastroenterology portfolio with the launch of AsacolTM 1g (mesalazine), a high-strength suppository for treating mild to moderate ulcerative proctitis symptoms in adults. This launch aims to provide innovative therapies for patients with gastrointestinal diseases, offering a convenient treatment option requiring only a single daily dose.
4. In April 2021, Teva Pharmaceuticals USA, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the launch of its generic version of Casana 1 (mesalamine) suppository medicine, indicated for treating active ulcerative proctitis (ulcerative rectal colitis) in the US.

Key companies profiled in the transmucosal drug delivery systems market report include Teva Pharmaceutical Industries Ltd, Cigna Corporation, BioDelivery Sciences International, Inc, 3M, Henkel Finland Oy, GlaxoSmithKline plc, Aquestive Therapeutics, Inc, Camurus AB, Ximedica, and Noven Pharmaceuticals, Inc. These leading players are focused on expanding and diversifying their market presence and clientele, seizing business opportunities in the market.

This product will be delivered within 3-5 business days.